Content about Pharmaceutical companies

January 7, 2010

A biopharmaceutical company announced the resignation of one of its executives....

January 7, 2010

Watson Labs, a subsidiary of specialty pharmaceutical company Watson Pharmaceuticals, has filed an abbreviated new...

January 6, 2010

Two drug makers have entered an agreement to develop a drug designed to treat melanoma....

January 4, 2010

A subsidiary of a generic drug maker has entered into a new licensing and development...

January 4, 2010

An India drug maker is in generic drug supply talks with two companies, according to...

January 3, 2010

With an eye to the future, Novartis brass envisions a growth arena driven by the...

NEW YORK With an eye to the future, Novartis brass envisions a growth arena driven by the aging Boomer population — eye care, along with all of the products, medicines and surgeries associated with eye care.

January 3, 2010

A generic drug maker has announced the availability of a treatment of the signs and...

December 31, 2009

Stymied by weak demand in a recessionary economy, intensifying generic competition, a relative dearth of research-and-development breakthroughs and an ongoing loss of patent protection for some of their biggest-selling pioneering medicines, branded pharmaceutical manufacturers have scrambled over the last three years to restore their once-enviable track record for product innovation and sales growth. And 2009 was no exception.

Stymied by weak demand in a recessionary economy, intensifying generic competition, a relative dearth of research-and-development breakthroughs and an ongoing loss of patent protection for some of their biggest-selling pioneering medicines, branded pharmaceutical manufacturers have scrambled over the last three years to restore their once-enviable track record for product innovation and sales growth. And 2009 was no exception. Click below to download the free PDF of ECRM Branded Rx 2010.

December 20, 2009

This is further substantiation that the business of over-the-counter medicines, particularly those sold in the...

NEW YORK This is further substantiation that the business of over-the-counter medicines, particularly those sold in the U.S. market, is a key growth driver for pharma companies. If you weren’t convinced when Pfizer re-entered the OTC market with its acquisition of Wyeth, then you certainly should be convinced now.

 

December 14, 2009

The ubiquitous universe of social media — comprised of blogs, microblogs, podcasts, social networks, video sharing sites and more — still holds many unanswered questions for some industry marketers. But there's one thing that is certain: Social media is changing the way consumers behave, and companies and brands must embrace and effectively plug into today's social world. Those that don't will be left in the dark. Find out how top retailers like Walgreens, CVS, Target, etc., as well as top industry suppliers like Boehringer Ingelheim, GlaxoSmithKline, Novartis and more, are plugging into the world of social media.

The ubiquitous universe of social media — comprised of blogs, microblogs, podcasts, social networks, video sharing sites and more — still holds many unanswered questions for some industry marketers. But there's one thing that is certain: Social media is changing the way consumers behave, and companies and brands must embrace and effectively plug into today's social world. Those that don't will be left in the dark.

December 3, 2009

The digestives aisle will be altogether crowded come early 2010, especially with two new proton-pump...

NEW YORK The digestives aisle will be altogether crowded come early 2010, especially with two new proton-pump inhibitors on the shelf. And while there may be some question as to just how large sales of antacids can get, one thing is for sure: There will be a slew of advertisers vying for their own increased share of stomach.

October 18, 2009

What’s really intriguing behind the return of a consumer division to Pfizer is the fact...

NEW YORK What’s really intriguing behind the return of a consumer division to Pfizer is the fact that two of its flagship pharmaceuticals -- Lipitor and Viagra -- are approaching patent expiration, and both have been suggested as possible Rx-to-OTC switch candidates by Kline & Co.

 

August 18, 2009

As seen on shelf at Walgreens, having a major pharma player like Bayer HealthCare field...

As seen on shelf at Walgreens, having a major pharma player like Bayer HealthCare field what essentially is a hangover-relief product adds credibility, not to mention a little more shelf presence, to similar products like Living Essentials’ Chaser Plus.

June 28, 2009

There was speculation in January that Schering-Plough’s switch application around the proton-pump inhibitor Zegerid was...

NEW YORK There was speculation in January that Schering-Plough’s switch application around the proton-pump inhibitor Zegerid was scuttled after receiving a complete response letter from the Food and Drug Administration.

 

April 9, 2009

A lot of news has been coming from the Food and Drug Administration lately. And...

A lot of news has been coming from the Food and Drug Administration lately. And that’s almost never good news for the pharmaceutical business.

 

The FDA recently has taken a number of regulatory actions against drug companies on matters ranging from marketing of unapproved drugs, to pulling unsafe drugs from the market, to drug advertising.

 

 

March 12, 2009

The last few weeks have seen a lot of acquisition activity among large pharmaceutical companies....

The last few weeks have seen a lot of acquisition activity among large pharmaceutical companies.

 

First, Pfizer announced in January that it would acquire Wyeth for approximately $68 billion. This month saw three more mergers: Merck & Co.’s $41.1 billion purchase of Schering-Plough Corp., Roche’s $46.8 billion purchase of Genentech and Gilead Science’s purchase of CV Therapeutics.

 

January 29, 2009

The deal gives a great deal of added heft to Pfizer’s pharmaceutical division — the...

The deal gives a great deal of added heft to Pfizer’s pharmaceutical division — the combined Pfizer/Wyeth entity represents $70 billion in annual sales. Pfizer was already the leading pharmaceutical supplier at retail pharmacy for the 12 months ending November according to IMS Health. And that’s thanks in large part to the company’s Lipitor franchise. While Lipitor is the No. 1 drug sold in retail pharmacy today, the first patent protecting the statin expires as soon as 2010, though most analysts project a generic Lipitor will be introduced by November 2011.

January 11, 2009

Par Pharmaceutical Cos. had total sales of $291.9 million and $26.3 million in profit for...

November 10, 2008

The situation is like having plans to bake a loaf of bread for dinner, but discovering at 5 p.m. that the flour is running low, and there is little time to go to the supermarket to buy more. Generic drug makers depend on a steady supply of expiring patents coming from large pharmaceutical companies for their business. In recent years, a whole slew of blockbuster drugs have come off patent, allowing generic drug makers to lap up the drug compounds. Over the next several years, however, the supply of expiring patents will begin to run dry. Between this year and 2016, $131 billion worth of drugs will come off patent, followed by a long decline often called the patent cliff. Facing this precipice, generic drug companies will have to adapt as the market becomes increasingly commoditized.

The situation is like having plans to bake a loaf of bread for dinner, but discovering at 5 p.m. that the flour is running low, and there is little time to go to the supermarket to buy more. Generic drug makers depend on a steady supply of expiring patents coming from large pharmaceutical companies for their business. In recent years, a whole slew of blockbuster drugs have come off patent, allowing generic drug makers to lap up the drug compounds. Over the next several years, however, the supply of expiring patents will begin to run dry.

September 22, 2008

The 1840s had the California Gold Rush. The 1990s had the tech boom. Years from now, historians might label the early 2000s the generic drugs rush. But whatever they call it, the big growth years may be behind the generic drug industry. In fact, some believe that over the course of the next five years or so, the boom even could go bust, as a shortage of big blockbuster drug launches today means a dropoff in the number of new generic introductions tomorrow — pointing to even stiffer competition for a generic drug market that grows steadily more commoditized.

The 1840s had the California Gold Rush. The 1990s had the tech boom. Years from now, historians might label the early 2000s the generic drugs rush. But whatever they call it, the big growth years may be behind the generic drug industry. In fact, some believe that over the course of the next five years or so, the boom even could go bust, as a shortage of big blockbuster drug launches today means a dropoff in the number of new generic introductions tomorrow — pointing to even stiffer competition for a generic drug market that grows steadily more commoditized.

September 19, 2007

Teva is introducing its generic to the Sanofi-Aventis anti-fungal medication Penlac nail lacquer....